KPRX logo

KIORA PHARMACEUTICALS INC

KPRXNASDAQ
๐Ÿ† #5064 by market capUS Equity
$0.75โ–ผ $0.24 (โˆ’24.24%)
Market closed ยท at close
๐Ÿ””
Track KPRX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 24.2%
7dโ–ผ 39.3%
14dโ–ผ 48.5%
30dโ–ผ 66.8%
ytdโ–ผ 61.5%
1yโ–ผ 58.9%
๐ŸฆMarket Cap
$3M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
0.2x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.75 โ€“ $0.78
52-Week Range
$0.72 โ€“ $2.91
Volume (shares)
1,503
Avg Volume (shares)
โ€”
Shares Outstanding
4.4M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
$1M
P/E Ratio
โ€”
P/S Ratio
0.2x
EPS (TTM)
$-2.47
Dividend Yield
โ€”
KPRX logo

KIORA PHARMACEUTICALS INC

KPRX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About KIORA PHARMACEUTICALS INC

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.